IRWD Share Price

Open 19.50 Change Price %
High 19.66 1 Day -0.03 -0.15
Low 19.27 1 Week 1.99 11.31
Close 19.58 1 Month 0.68 3.60
Volume 1120386 1 Year 7.34 59.97
52 Week High 19.94
52 Week Low 12.02
IRWD Important Levels
Resistance 2 19.94
Resistance 1 19.79
Pivot 19.50
Support 1 19.37
Support 2 19.22
NASDAQ USA Most Active Stocks
YHOO 52.58 0.00%
YHOO 52.58 0.00%
YHOO 52.58 0.00%
DCTH 0.16 -33.33%
FTR 1.22 8.93%
FTR 1.22 8.93%
ASTI 0.00 0.00%
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
More..
NASDAQ USA Top Gainers Stocks
OPXAW 0.12 200.00%
AVEO 1.25 71.23%
LOCM 0.09 50.00%
MYRX 0.09 50.00%
SNCR 16.24 33.33%
QUIK 1.60 31.15%
WRES 0.09 28.57%
IIN 8.35 27.48%
IIN 8.35 27.48%
IIN 8.35 27.48%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
TOPS 0.80 -66.67%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
SPIR 0.01 -50.00%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
More..

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD)

IRWD Technical Analysis 5
As on 23rd Jun 2017 IRWD Share Price closed @ 19.58 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 15.75 & Strong Buy for SHORT-TERM with Stoploss of 17.28 we also expect STOCK to react on Following IMPORTANT LEVELS.
IRWD Target for June
1st Target up-side 20.14
2nd Target up-side 21.84
3rd Target up-side 23.55
1st Target down-side 15.28
2nd Target down-side 13.58
3rd Target down-side 11.87
IRWD Other Details
Segment EQ
Market Capital 1211006720.00
Sector Healthcare
Industry Drugs - Generic
Offical website http://www.ironwoodpharma.com
IRWD Address
IRWD
301 Binney Street
Cambridge, MA 02142
United States
Phone: 617-621-7722
Fax: 617-494-0480
IRWD Latest News
Interactive Technical Analysis Chart Ironwood Pharmaceuticals, Inc. ( IRWD NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Ironwood Pharmaceuticals, Inc.
IRWD Business Profile
Ironwood Pharmaceuticals, Inc. is a pharmaceutical company, which discovers, develops and intends to commercialize differentiated medicines. The Company is engaged in the area of guanylate cyclase type-C (GC-C), agonists and in the science and treatment of gastrointestinal diseases. Its two GC-C agonists are linaclotide and IW-9179.